Why are researchers still fumbling in the quest to cure what is arguably one of the most important diseases confronting humankind — Alzheimer’s disease?…
Anti-amyloid drugs like Leqembi and Kisunla are on the market for treating early Alzheimer’s disease, but they are expensive, difficult to access, and only…
Women were historically excluded from medical research. The move was originally intended to keep them safe — but in a way, it did the…
When the COVID-19 pandemic hit in 2019, researchers raised concerns it would increase the risk of neurodegenerative diseases like Alzheimer’s and Parkinson’s. A recent…
There’s a hereditary typo in Doug Whitney’s genetic code: a variant that all but guarantees its carriers will contract Alzheimer’s disease within their lifetime….
From clinical trials to funding cuts: Here’s how changes at NIH are reshaping Alzheimer’s and dementia research. As of September 2024, 495 clinical trials…
Long COVID, a baffling constellation of physical symptoms that may persist long after a bout of COVID-19, can strike almost every system in the…
Can a seemingly harmless virus in the gut wreak havoc on the brain decades after the initial infection? And could catching and treating an…
In the brains of people with Alzheimer’s diseases, problematic proteins called beta-amyloid build up and clump together in plaques, harming and eventually killing off…
There currently no cure or treatment that can completely halt or reverse Alzheimer’s pathology in the brain. One of the biggest obstacles: Even after…
Heralded as a longevity treatment for bio-hacking enthusiasts and tech CEOs, therapeutic plasma exchange also has applications for people concerned about inflammatory diseases like…
After months of delays, Alzheon gears up to present data from their pivotal Phase 3 drug trial, while Athira Pharma pays out a settlement…
ApoE4, a genetic variation sometimes referred to as the “Alzheimer’s gene,” is one of the most influential genetic risk factors for developing Alzheimer’s disease….
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
Light pollution is a growing issue. Over the past 25 years, artificial lighting has surged by 49% worldwide. For perspective, the brightness of the…